PFE vs BMY — Key Metrics

Metric PFE (PFIZER INC) BMY (BRISTOL MYERS SQUIBB CO)
Price28.0659.56
Market Cap159.94 Billion121.75 Billion
P/E (TTM)39.5213.15
P/B (Quarterly)1.9215.362
P/S (TTM)2.512.43
Net Profit Margin (TTM)6.318.5
Gross Margin (TTM)73.469.2
ROE (TTM)4.643.9
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

PFIZER INC
vs
 
BRISTOL MYERS SQUIBB CO
 
PFIZER INC
vs
 
BRISTOL MYERS SQUIBB CO
Performance Comparison
AI Model Recommendation
PFE · PFIZER INC

Greatly Outperform

91
UnderperformOutperform
BMY · BRISTOL MYERS SQUIBB CO

Greatly Outperform

87
UnderperformOutperform
Recommendation Summary

Both stocks are projected to significantly outperform the market over the next year. If you have to make a choice, Upfront Recommendation: PFE.

Financial Metrics
Prices delayed ~15 min
PFE Metrics BMY
$28.06 Price $59.56
— Market Capitalization —
39.52 Price to Earnings Ratio 13.15
2.51 Price to Sales 2.43
13.57 Price to FCF Ratio 13.11
3.43 Price to Gross Profit 3.51
13.88 Price to R&D 11.53
3.55 Price to Current Assets 4.09

PFE vs BMY at a glance

Pfizer INC (PFE) and Bristol Myers Squibb CO (BMY) are both Drug Manufacturers - General companies in the Healthcare sector. PFE is the larger, at $159.9 billion in market value against $121.7 billion for BMY, about 1.3 times the size.

On trailing-twelve-month figures, PFE trades at 39.5 times trailing earnings and BMY at 13.2; net profit margins are 6.3% and 18.5%.

The Upfront Investment model currently rates both Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.